CA2795362C - Compositions and methods for prediction of drug sensitivity, resistance, and disease progression - Google Patents

Compositions and methods for prediction of drug sensitivity, resistance, and disease progression Download PDF

Info

Publication number
CA2795362C
CA2795362C CA2795362A CA2795362A CA2795362C CA 2795362 C CA2795362 C CA 2795362C CA 2795362 A CA2795362 A CA 2795362A CA 2795362 A CA2795362 A CA 2795362A CA 2795362 C CA2795362 C CA 2795362C
Authority
CA
Canada
Prior art keywords
protein
sample
modulator
subject
indicative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2795362A
Other languages
English (en)
French (fr)
Other versions
CA2795362A1 (en
Inventor
Douglas P. Clark
Adam Schayowitz
Cirilo Cabradilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarker Strategies LLC
Original Assignee
Biomarker Strategies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarker Strategies LLC filed Critical Biomarker Strategies LLC
Publication of CA2795362A1 publication Critical patent/CA2795362A1/en
Application granted granted Critical
Publication of CA2795362C publication Critical patent/CA2795362C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2795362A 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression Active CA2795362C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15
PCT/US2011/032935 WO2011133477A2 (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Publications (2)

Publication Number Publication Date
CA2795362A1 CA2795362A1 (en) 2012-10-02
CA2795362C true CA2795362C (en) 2018-03-20

Family

ID=44834747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795362A Active CA2795362C (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Country Status (12)

Country Link
US (1) US9766249B2 (enExample)
EP (1) EP2561368B1 (enExample)
JP (2) JP6158078B2 (enExample)
KR (1) KR101977875B1 (enExample)
CN (2) CN102947706B (enExample)
AU (1) AU2011242990B2 (enExample)
CA (1) CA2795362C (enExample)
ES (1) ES2650674T3 (enExample)
HK (1) HK1258688A1 (enExample)
PL (1) PL2561368T3 (enExample)
SG (1) SG184507A1 (enExample)
WO (1) WO2011133477A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
TW201601753A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 蛋白質生物標記及其用途
WO2022187196A1 (en) * 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
CN107922504B (zh) * 2015-07-07 2021-07-30 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
EP4185870A1 (en) * 2020-07-24 2023-05-31 Genentech, Inc. Determining hemodilution of bone marrow aspirates using biomarkers
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR20240037082A (ko) * 2022-09-14 2024-03-21 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US20060188895A1 (en) * 2004-08-31 2006-08-24 The Johns Hopkins University Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
US8841076B2 (en) * 2005-05-09 2014-09-23 Theranos, Inc. Systems and methods for conducting animal studies
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2006133399A1 (en) 2005-06-08 2006-12-14 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
EP1937314A4 (en) 2005-09-01 2009-01-07 Bristol Myers Squibb Co BIOMARKERS AND PROCEDURE FOR DETERMINING SENSITIVITY FOR VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 2 MODULATORS
WO2007143183A2 (en) 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
EP2210080B1 (en) 2007-10-24 2015-01-28 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
EP2220503A1 (en) * 2007-11-30 2010-08-25 Schering Corporation Braf biomarkers

Also Published As

Publication number Publication date
EP2561368A4 (en) 2013-10-09
JP6580546B2 (ja) 2019-09-25
HK1258688A1 (zh) 2019-11-15
JP6158078B2 (ja) 2017-07-05
PL2561368T4 (pl) 2018-03-30
CN108535465A (zh) 2018-09-14
EP2561368B1 (en) 2017-08-02
EP2561368A2 (en) 2013-02-27
KR101977875B1 (ko) 2019-05-13
AU2011242990A1 (en) 2012-11-01
WO2011133477A2 (en) 2011-10-27
AU2011242990B2 (en) 2015-02-12
CN102947706B (zh) 2018-04-13
PL2561368T3 (pl) 2018-03-30
US9766249B2 (en) 2017-09-19
WO2011133477A3 (en) 2012-05-10
JP2017106923A (ja) 2017-06-15
CA2795362A1 (en) 2012-10-02
JP2013525786A (ja) 2013-06-20
SG184507A1 (en) 2012-11-29
US20120094853A1 (en) 2012-04-19
ES2650674T3 (es) 2018-01-19
CN102947706A (zh) 2013-02-27
KR20130095183A (ko) 2013-08-27

Similar Documents

Publication Publication Date Title
CA2795362C (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
JP7108323B2 (ja) 細胞全体でのアッセイおよび方法
JP6782698B2 (ja) がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
Quezada et al. Omics-based biomarkers: current status and potential use in the clinic
Korde et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
Blumenthal et al. Methods and goals for the use of in vitro and in vivo chemosensitivity testing
JP7264484B2 (ja) 治療剤選択のためのシグナル伝達経路活性の測定方法
US20080108091A1 (en) Proteomic Patterns of Cancer Prognostic and Predictive Signatures
US20170184594A1 (en) Pathway characterization of cells
WO2015089380A2 (en) Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
Neagu et al. Protein microarray technology: Assisting personalized medicine in oncology
Morris Genomic and proteomic profiling for cancer diagnosis in dogs
Wang et al. Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
Li et al. Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization
Hammond et al. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003
Hoff et al. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges
Zhu et al. Single-cell transcriptome analysis reveals estrogen signaling augments the mitochondrial folate pathway to coordinately fuel purine and polyamine synthesis in breast cancer cells
Young A translational study in pancreatic neuroendocrine neoplasms
Ly et al. epithelial cells [version 1; referees: awaiting peer review]
Awaji Utilization of High Throughput Screening to Identify Therapeutic Targets for Defective MCPH1/BRIT1 Function-Induced Premature Chromosome Condensation in Breast and Ovarian Cancer.
Ramos Characterization of Small Cell Carcinoma of the Ovary, Hypercalcemic Type

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160225